Építés alatt – nem éles oldal
Belépés

What researchers published on Mieloproliferatív neopláziák

7965 papers, newest first.

Showing 20 of 7965

  • ÁttekintésPolycythemia vera and JAK2 unmutated erythrocytosis: Overview of updates in diagnosis and management from 2026.Therapeutic advances in hematology
  • ÁttekintésThrombotic and Hemorrhagic Events in Myeloproliferative Neoplasms.Current hematologic malignancy reports
  • A novel DMTN::HMGA2 rearrangement drives aberrant reactivation of HMGA2 with profibrotic and type I interferon-suppressive signaling.Cancer biology & therapy
  • SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score-matched cohort study.Frontiers in endocrinology
  • Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey.Expert review of hematology
  • EHA Guidelines for the use and reporting of patient-reported outcomes in clinical trials of classical Philadelphia chromosome-negative myeloproliferative neoplasms.HemaSphere
  • EsetismertetésDigital Necrosis as an Initial Manifestation of a Myeloproliferative Neoplasm.Plastic and reconstructive surgery. Global open
  • Stem cell source, CD34+ dose and outcomes in haploidentical hematopoietic cell transplantation for myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.Bone marrow transplantation
  • European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib.Leukemia
  • CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.Blood
  • How I diagnose myeloid or lymphoid neoplasms with tyrosine kinase gene fusions.American journal of clinical pathology
  • Low dose pre-transplant splenic radiotherapy for myeloproliferative neoplasms.Leukemia & lymphoma
  • Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial.Future oncology (London, England)
  • The new Iron Age in polycythemia vera.Blood
  • EsetismertetésThrombocytapheresis for Extreme Thrombocytosis: A 20-Year Single-Center Experience With Acute and Chronic Use in Myeloproliferative Neoplasms.Journal of clinical apheresis
  • EsetismertetésCase Report: Real-world experience with pacritinib after prior ruxolitinib exposure in myelofibrosis in Saudi Arabia: a report of five cases.Frontiers in medicine
  • Hematological trajectories and pregnancy complications in essential thrombocythemia and polycythemia vera.Annals of hematology
  • Effects of calreticulin mutations on HLA class I expression in myeloproliferative neoplasms.JCI insight
  • Portal and hepatic vein thrombosis in Philadelphia-negative myeloproliferative neoplasms: Insights from the National Inpatient Sample.Thrombosis research
  • ÁttekintésSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia